Imine reductase mutant and application thereof in preparation of tofacitinib chiral amine block
The synthesis of tofatinib chiral amine blocks catalyzed by imine reductase and its mutant has solved the problem of low product purity and yield in the existing methods, and achieved efficient and simple tofatinib chiral amine Block production reduces production costs and avoids high temperature and high pressure conditions.
Patent Information
- Application Number
- CN202411086795.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-08
AI Technical Summary
The existing tofatinib chiral amine block synthesis process is complicated, the optical purity and yield of the product are low, and high temperature and high pressure conditions are required, resulting in high production costs and unsafe factors.
Imine reductase and its mutant catalytic racemic ketone substrate for dynamic kinetic resolution and asymmetric reduction amination, synthesize a single configuration of tofatinib chiral amine blocks, and use recombinant expression carriers and catalysts Improve catalytic efficiency and stability.
The efficient and simple synthesis of tofatinib chiral amine blocks was achieved, with the optical purity of the product reaching 99.9%, and the dr value was greater than 98:2, reducing production costs and avoiding the harsh environment of high temperature and high pressure.
Smart Images

Figure CN118909992A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of bioengineering technology, and specifically relates to an imine reductase, an imine reductase mutant, a gene encoding the same, a recombinant expression vector and a recombinant expression transformant containing the same, a recombinant imine reductase catalyst and a preparation method thereof, and an application of the imine reductase mutant or the recombinant imine reductase catalyst in the preparation of a tofacitinib chiral amine building block. Background Art
[0002] Tofacitinib is a Janus activated kinase inhibitor containing a bimanual amine structure, which can be used to treat rheumatoid arthritis, psoriasis and prevent organ transplant immune rejection. Tofacitinib was launched in China on March 10, 2017 as China's first oral small molecule drug for the treatment of rheumatoid arthritis and other diseases. Due to its unique targeting mechanism, safety of treatment, oral convenience, and high compliance, Tofacitinib has attracted widespread attention at home and abroad since its launch. In the 2020 list of the top 200 drug retail sales, Tofacitinib ranked 65th, with global sales of US$2.47 billion.
[0003] The molecule of tofacitinib is mainly composed of three parts: a disubstituted piperidine ring, a pyrimidopyrrole bicyclic ring and a cyanoacetate side chain. The main challenges and costs of the synthesis of this drug are the synthesis of its multi-chiral amine building blocks. In 2002, Pfizer first reported the molecular assembly strategy of tofacitinib (WO2002096909). The first is the aromatic nucleophilic substitution reaction (S) of chloropyrrolopyrimidine with the chiral amine building block. N Ar reaction), followed by hydrogenation to remove the benzyl protecting group, and finally adding the side chain of cyanoacetate. Among them, chloropyrrolopyrimidine is relatively cheap, and benzyl protection of the piperidine ring is also relatively convenient, so this assembly strategy has been widely used in the future. In 2007, Pfizer improved this process, using dichloropyrrolopyrimidine to have a higher yield than monochloropyrrolopyrimidine, and an extra chlorine can be removed when hydrogenating to remove the benzyl group (WO2007012953). After many years of improvement, there is also a method of using p-toluenesulfonyl (Ts) to protect chloropyrrolopyrimidine in order to improve the product yield and reduce the generation of by-products.
[0004] In 2002, Pfizer developed a method for preparing the bimanual amine building block of tofacitinib. A racemic mixture of four configurations was obtained from piperidone through reductive amination, and then the racemate was separated by recrystallization. Since piperidone is difficult to support large-scale industrial production, in 2003, Pfizer used methyl pyridine as a precursor, benzyl protection, sodium borohydride reduction to alcohol, and finally oxidation to piperidone. This made it possible to prepare kilogram-level bimanual amine building blocks of tofacitinib (Org Process Res Dev, 2003, 7: 2168-2172). In 2004 and 2007, Pfizer used heavy metal-bound chiral ligand-catalyzed asymmetric hydrogenation to improve the original preparation process of bimanual amine building blocks of tofacitinib (Org Process Res Dev, 2005, 9: 51–56).
[0005] In recent years, the method of asymmetric reductive amination or asymmetric hydrogenation catalyzed by transition metals combined with chiral ligands has been used to prepare the bimanual amine building blocks of tofacitinib. Chengxi Li et al. developed a method of synthesizing bimanual amine building blocks of tofacitinib by asymmetric hydrogenation catalyzed by rhodium and chiral ligands, with a yield of 98% and an er value of 98:2, but the catalyst conversion number is low (TON < 400), and subsequent multi-step reactions are required to obtain the final chiral amine building block product, and the process is relatively cumbersome. In addition, the preparation method requires 500psi high-pressure H2 (Angew Chem Int Ed, 2019, 58: 13573–13583). This requires additional high-pressure hydrogen equipment, which further increases the production cost and introduces unsafe factors in production.
[0006] In 2013, Santos developed a method for preparing tofacitinib through chiral alcohol intermediates, but the overall yield was low, only 9.5% (Tetrahedron Lett, 2013, 54: 5096–5098.). In 2018, Kamble improved the preparation process of chiral alcohol building blocks, but its synthesis route was long, using metal catalysts and chiral ligands, and the final yield after eight steps of reaction was less than 20% (98% ee), and there were more by-products (Synth Commun, 2018, 48: 1045–1051). Obviously, the method of introducing the chiral center of tofacitinib through chiral alcohol is not suitable for industrial production.
[0007] In summary, the current synthesis method of tofacitinib chiral amine building blocks usually relies on the resolution of racemates. However, this method is cumbersome and requires repeated resolution to achieve sufficient optical purity. Moreover, the racemate of the chiral center has four configurations, and the theoretical yield of the product is only 25% at most. In addition, the asymmetric synthesis method requires the use of transition metals and chiral ligands. They are not only expensive, but also difficult to remove during the subsequent separation and purification of the product. In addition, chemical asymmetric catalysis usually needs to be carried out under harsh conditions of high temperature and high pressure, which not only generates a large amount of by-products, but also has low optical purity and yield of the product. Therefore, it is very necessary to develop a more efficient, simple and green synthesis process for tofacitinib chiral amine building blocks. Summary of the invention
[0008] In view of the problems of strict process conditions, low product yield and insufficient optical purity in the existing chemical method for producing tofacitinib chiral amine building blocks, the present invention provides an imine reductase and its mutants, a nucleic acid encoding the imine reductase and its mutants, a recombinant expression vector containing the nucleic acid, a recombinant expression transformant containing the recombinant expression vector, a recombinant imine reductase catalyst and its use in synthesizing tofacitinib chiral amine building blocks.
[0009] The imine reductase and its mutant provided by the invention have high expression amount, strong catalytic activity, high stability, good stereoselectivity and a wide catalytic substrate spectrum.
[0010] The imine reductase or the imine reductase mutant of the present invention can catalyze the dynamic kinetic resolution and asymmetric reductive amination of a racemic precursor ketone substrate to synthesize a single-configuration tofacitinib chiral amine building block.
[0011] The purpose of the present invention can be achieved by the following technical solutions:
[0012] The first object of the present invention is to provide an isolated imine reductase, the amino acid sequence of the imine reductase is shown in SEQ ID No. 1, and the imine reductase is PociRED.
[0013] The second object of the present invention is to provide an imine reductase mutant, which is a protein corresponding to a sequence derived from the amino acid sequence shown in SEQ ID No.1 after amino acid substitution, deletion or insertion of one or more amino acid residues, and the imine reductase mutant has superior properties to the imine reductase corresponding to the amino acid sequence shown in SEQ ID No.1.
[0014] Furthermore, the imine reductase mutant is a derivative protein having a new amino acid sequence formed by replacing one or more amino acid residues of glycine at position 239, proline at position 125, serine at position 40, valine at position 124, isoleucine at position 127, leucine at position 128, serine at position 72, tyrosine at position 73, threonine at position 76, lysine at position 195, glycine at position 180, arginine at position 220, alanine at position 47, valine at position 50, phenylalanine at position 210, lysine at position 212, tryptophan at position 217, isoleucine at position 178, histidine at position 224 or leucine at position 236 as shown in SEQ ID No.1 with other amino acid residues. The protein has significantly improved reductive amination activity and stereoselectivity for racemic precursor ketones of the corresponding tofacitinib chiral amine building blocks compared to the imine reductase corresponding to the amino acid sequence shown in SEQ ID No. 1, and also has improved expression and stability.
[0015] In some embodiments of the present invention, the amino acid sequence of the specific imine reductase mutant is one of the following sequences:
[0016] (1) the glutamine at position 239 of the amino acid sequence shown in SEQ ID No. 1 is replaced by glycine, the proline at position 125 is replaced by threonine, and the serine at position 40 is replaced by glutamic acid;
[0017] (2) the serine at position 72 of the amino acid sequence shown in SEQ ID No. 1 is replaced by asparagine, the tyrosine at position 73 is replaced by glutamine, the threonine at position 76 is replaced by valine, the lysine at position 195 is replaced by alanine, and the glycine at position 180 is replaced by serine;
[0018] (3) in the amino acid sequence shown in SEQ ID No. 1, the proline at position 125 is replaced by threonine, the serine at position 40 is replaced by glutamic acid, the valine at position 124 is replaced by threonine, the isoleucine at position 127 is replaced by glutamic acid, the leucine at position 128 is replaced by tyrosine, the serine at position 72 is replaced by asparagine, the tyrosine at position 73 is replaced by glutamine, and the threonine at position 76 is replaced by valine;
[0019] (4) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, lysine at position 195 is replaced by alanine, glycine at position 180 is replaced by serine, and arginine at position 220 is replaced by valine;
[0020] (5) replacing the proline at position 125 of the amino acid sequence shown in SEQ ID No. 1 with threonine;
[0021] (6) in the amino acid sequence shown in SEQ ID No. 1, the phenylalanine at position 210 is replaced by leucine, the lysine at position 212 is replaced by alanine, the tryptophan at position 217 is replaced by glutamine, the isoleucine at position 178 is replaced by valine, the histidine at position 224 is replaced by arginine, and the leucine at position 236 is replaced by isoleucine;
[0022] (7) in the amino acid sequence shown in SEQ ID No. 1, the arginine at position 220 is replaced by valine, the alanine at position 47 is replaced by proline, the valine at position 50 is replaced by alanine, the phenylalanine at position 210 is replaced by leucine, the lysine at position 212 is replaced by alanine, the tryptophan at position 217 is replaced by glutamine, the isoleucine at position 178 is replaced by valine, the histidine at position 224 is replaced by arginine, and the leucine at position 236 is replaced by isoleucine;
[0023] (8) the glutamine at position 239 of the amino acid sequence shown in SEQ ID No. 1 is replaced by glycine, the proline at position 125 is replaced by threonine, and the serine at position 40 is replaced by glutamic acid;
[0024] (9) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, lysine at position 195 is replaced by alanine, glycine at position 180 is replaced by serine, arginine at position 220 is replaced by valine, alanine at position 47 is replaced by proline, valine at position 50 is replaced by alanine, phenylalanine at position 210 is replaced by leucine, and lysine at position 212 is replaced by alanine;
[0025] (10) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, lysine at position 195 is replaced by alanine, glycine at position 180 is replaced by serine, arginine at position 220 is replaced by valine, alanine at position 47 is replaced by proline, valine at position 50 is replaced by alanine, phenylalanine at position 210 is replaced by leucine, lysine at position 212 is replaced by alanine, tryptophan at position 217 is replaced by glutamine, isoleucine at position 178 is replaced by valine, histidine at position 224 is replaced by arginine, and leucine at position 236 is replaced by isoleucine;
[0026] (11) replacing the glutamine at position 239 of the amino acid sequence shown in SEQ ID No. 1 with glycine;
[0027] (12) the glutamine at position 239 of the amino acid sequence shown in SEQ ID No. 1 is replaced by glycine, and the proline at position 125 is replaced by threonine;
[0028] (13) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, and leucine at position 128 is replaced by tyrosine;
[0029] (14) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, and lysine at position 195 is replaced by alanine;
[0030] (15) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, lysine at position 195 is replaced by alanine, glycine at position 180 is replaced by serine, arginine at position 220 is replaced by valine, alanine at position 47 is replaced by proline, and valine at position 50 is replaced by alanine;
[0031] (16) In the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, and lysine at position 195 is replaced by The amino acid residues at position 170 were replaced by alanine, the glycine at position 180 was replaced by serine, the arginine at position 220 was replaced by valine, the alanine at position 47 was replaced by proline, the valine at position 50 was replaced by alanine, the phenylalanine at position 210 was replaced by leucine, the lysine at position 212 was replaced by alanine, the tryptophan at position 217 was replaced by glutamine, the isoleucine at position 178 was replaced by valine, the histidine at position 224 was replaced by arginine, and the leucine at position 236 was replaced by isoleucine.
[0032] The above imine reductase mutant can be obtained by the following technical scheme:
[0033] Using the imine reductase PocIRED with an amino acid sequence as shown in SEQ ID No. 1 as the parent, a number of imine reductase mutants with significantly improved imine reductase reductive amination activity were identified through random mutagenesis combined with high-throughput primary screening and further shake flask culture rescreening.
[0034] The third object of the present invention is to provide an isolated nucleic acid encoding the imine reductase or any imine reductase mutant.
[0035] Furthermore, the nucleic acid sequence encoding the imine reductase PociRED is shown in SEQ ID No.3.
[0036] The nucleic acid sequence encoding any one of the imine reductase mutants is a nucleic acid sequence derived from the nucleic acid sequence shown in SEQ ID No. 3 by base substitution, deletion or insertion of 3 or multiples of 3 bases.
[0037] The fourth object of the present invention is to provide a recombinant expression vector, which comprises the nucleic acid described in the third object of the present invention.
[0038] In one embodiment of the present invention, the recombinant expression vector is a pET28a plasmid vector containing an editing gene of imine reductase or a mutant thereof.
[0039] The fifth object of the present invention is to provide a recombinant expression transformant, which comprises the recombinant expression vector.
[0040] In one embodiment of the present invention, the recombinant expression transformant is Escherichia coli containing the recombinant expression vector and expressing imine reductase or an imine reductase mutant.
[0041] In one embodiment of the present invention, the Escherichia coli is E. coli (DE3).
[0042] The sixth object of the present invention is to provide a method for constructing the recombinant expression transformant, comprising the following steps:
[0043] (1) Construction of a recombinant expression vector: inserting the imine reductase (IRED) or imine reductase mutant (IRED mutant) gene into the NdeⅠ / HindⅢ restriction site on the pET28a plasmid to obtain a recombinant expression vector pET28a-IRED or pET28a-IRED mutant;
[0044] (2) Transforming the recombinant expression vector pET28a-IRED or the pET28a-IRED mutant into an Escherichia coli expression host, and screening positive transformants to obtain the recombinant expression transformant.
[0045] The seventh object of the present invention is to provide a recombinant imine reductase catalyst, wherein the recombinant imine reductase catalyst is in any one of the following forms:
[0046] (1) culturing the recombinant expression transformant of the present invention, and isolating transformant cells containing the imine reductase or the imine reductase mutant;
[0047] (2) culturing the recombinant expression transformant of the present invention and isolating a crude enzyme solution containing the imine reductase or the imine reductase mutant;
[0048] (3) culturing the recombinant expression transformant of the present invention, isolating transformant cells containing the imine reductase or imine reductase mutant, and disrupting the transformant cells to obtain a cell disrupted liquid;
[0049] (4) culturing the recombinant expression transformant of the present invention, isolating transformant cells containing the imine reductase or the imine reductase mutant, disrupting the transformant cells to obtain a cell disrupted liquid, and freeze-drying the cell disrupted liquid to obtain a freeze-dried enzyme powder;
[0050] Among them, in order to obtain the recombinant imine reductase catalyst, the culture method and conditions of the recombinant expression transformant are conventional methods and conditions in the art. For example, in one embodiment, the culture method of the recombinant expression transformant comprises the following steps: culturing the recombinant expression transformant of the present invention to obtain a recombinant imine reductase mutant. For recombinant Escherichia coli, the preferred culture medium is LB medium: peptone 10g / L, yeast extract 5g / L, NaCl 10g / L, pH 6.5-7.0. The preferred culture method is: inoculate the recombinant Escherichia coli constructed as described above into LB medium containing kanamycin, and culture overnight at 37°C and 180rpm. Inoculate into a 500ml Erlenmeyer flask containing 100ml of LB medium (containing kanamycin) at an inoculum size of 1-2% (v / v), place it in a shaker at 37°C and 180rpm for shaking culture, and when the OD of the culture solution reaches 400,000, the culture medium is inoculated with 100ml of LB medium (containing kanamycin). 600 When the pH reaches 0.6-0.8, add isopropyl-β-D-thiogalactoside (IPTG) with a final concentration of 0.1-0.5mmol / L as an inducer, and after induction at 16-25°C for 16-24h, centrifuge the culture solution, collect the precipitate, and then wash it twice with physiological saline to obtain recombinant expression transformant cells. The harvested recombinant cells are freeze-dried to obtain frozen stem cells containing the IRED or IRED mutant. The harvested recombinant cells are suspended in a buffer solution with a volume of 5-10 times (v / w), ultrasonically broken, and centrifuged to collect the supernatant to obtain the crude enzyme solution of the IRED or IRED mutant. The collected crude enzyme solution is frozen at -80°C, and then low-temperature dried using a vacuum freeze dryer to obtain crude enzyme powder. The obtained crude enzyme powder is stored in a 4°C refrigerator for easy use.
[0051] The eighth object of the present invention is to provide the use of the imine reductase or the imine reductase mutant or the recombinant imine reductase catalyst, specifically, the use of the imine reductase or the imine reductase mutant or the recombinant imine reductase catalyst in catalyzing the asymmetric reductive amination reaction of a racemic ketone substrate to synthesize the chiral amine building block of tofacitinib.
[0052] In one embodiment of the present invention, the imine reductase or imine reductase mutant or recombinant imine reductase catalyst catalyzes the asymmetric reductive amination reaction of the racemic ketone substrate, and the coenzyme NADPH is oxidized to NADP + , using dehydrogenase to catalyze NADP + Reduction regenerates to NADPH.
[0053] The dehydrogenase is an enzyme catalyst for coenzyme circulation in the asymmetric reductive amination reaction of racemic ketone substrate catalyzed by an auxiliary imine reductase or an imine reductase mutant or a recombinant imine reductase catalyst.
[0054] In one embodiment of the present invention, the dehydrogenase is any one of the following dehydrogenases:
[0055] (1) Formate dehydrogenase FDH (Enzyme Microb Tech, 2010, 45: 557-561);
[0056] (2) Glucose dehydrogenase GDH (ChemBioChem, 2020, 21: 2680-2688);
[0057] (3) Alcohol dehydrogenase ADH (J Am Chem Soc, 1986, 108: 162-169).
[0058] In one embodiment of the present invention, the racemic substrate ketone for synthesizing the chiral amine building block of tofacitinib is selected from any of the following compounds represented by the chemical formula:
[0059]
[0060] In one embodiment of the present invention, the substrate is 1-benzyl-4-methylpiperidin-3-one, and the tofacitinib chiral amine building block is 3R,4R-1-benzyl-N,4-dimethylpiperidin-3-amine.
[0061] Compared with the prior art, the technical effects of the present invention are mainly reflected in the following aspects:
[0062] The present invention provides an imine reductase, an imine reductase mutant, a nucleic acid encoding the imine reductase or the imine reductase mutant, a recombinant expression vector containing the nucleic acid, a recombinant expression transformant containing the recombinant expression vector, a recombinant imine reductase catalyst, and use of the recombinant imine reductase catalyst in preparing a tofacitinib chiral amine building block.
[0063] The imine reductase and the imine reductase mutant have high expression levels and can efficiently catalyze the tofacitinib racemic precursor ketone to generate a single-configuration chiral amine product through dynamic kinetic resolution and asymmetric amination reaction.
[0064] Among them, the methods and conditions for the dynamic kinetic resolution and asymmetric amination reaction of the racemic precursor ketone substrate of the tofacitinib chiral amine building block catalyzed by the imine reductase and the imine reductase mutant are conventional methods and conditions in the art. In some optional embodiments, the reaction system includes a substrate racemic ketone (for example, the substrate 1-benzyl-4-methylpiperidin-3-one) at a concentration of 1-200 g / L, a corresponding amine donor (methylamine) to substrate molar ratio of 1.0-10.0, a glucose to substrate molar ratio of 1.0-2.0, and NADP +The addition amount is 0.05-2.0mmol / L, the molar ratio of cosubstrate glucose to substrate is 1.0-3.0, the activity ratio of coenzyme dehydrogenase to imine reductase is 1.0-3.0, pH is 5.0-10.0, and the temperature is 20-40°C. Samples are taken intermittently during the reaction. The conversion rate of the reaction is detected, and the reaction is stopped when the conversion rate reaches more than 90% or the conversion rate no longer continues to increase. The ee value of the product can reach more than 99.9%, and the dr value is greater than 98:2.
[0065] Compared with other chemical or biological catalysts for preparing optically pure tofacitinib chiral amine building blocks, the imine reductase and its imine reductase mutant provided by the present invention have high expression level, strong catalytic activity, high stability, good stereoselectivity and a wide catalytic substrate spectrum, showing broad application prospects in industrial applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0066] Figure 1 The performance characterization results of the imine reductase PocIRED parent (WT) and its mutant (M6) catalyzing the racemic 1-benzyl-4-methylpiperidin-3-one substrate and its analogs. DETAILED DESCRIPTION
[0067] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments.
[0068] Each reaction or detection condition described in the content of the present invention can be combined or changed according to the common sense in the art, and can be verified by experiments. The technical scheme and technical effects of the present invention will be clearly and completely described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited to these embodiments, and any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention.
[0069] The sources of materials in the following examples are:
[0070] The plasmid vector pET28a was purchased from Novagen.
[0071] E. coli DH5α and E. coli BL21 (DE3) competent cells, 2× Taq PCR MasterMix, and agarose gel DNA recovery kit were purchased from Beijing Tiangen Biochemical Technology Co., Ltd.
[0072] The chiral GC analysis method is as follows:
[0073] Instrument: Shimadzu GC-2014; Column model: Agilent CP-Chirasil (25m×0.25mm×0.25mm); Analysis method: 130℃, hold for 30min, 10℃ min -1to 180℃, hold for 10min;
[0074] The high-throughput UPLC analysis method is as follows:
[0075] Instrument: Shimadzu LC-30AD UPLC; Chromatographic column: Shim-pack GIST (2.1×50mm, 2um); Analytical method: isocratic: A phase (MeOH): B phase (H2O+0.1% diethylamine and 0.05% trifluoroacetic acid) = 8:2; Flow rate: 1.5mL / mL; Column temperature: 40℃; Injection volume: 2μL; Detector: UV detector; Detection wavelength: 205nm.
[0076] Example 1: Screening of Imine Reductase
[0077] The present embodiment provides an imine reductase Pocired derived from Pochonia chlamydosporia, which is obtained by screening the inventor from an imine reductase enzyme library previously constructed in his laboratory.
[0078] The amino acid sequence of the imine reductase PociRED is shown in SEQ ID No. 1. Specifically, it is as follows:
[0079] MSSSNKPHVS LIGLGNMGLA IANCLIKSGC KLTVWNRSAS KAASLVAQGV TVAATPAECV 60
[0080] ASSPTIVICL LSYDVTQQTL DEVIDLSGKT IINLTNGTPQ QAVKVATLVQ QRGAESYIHG 120
[0081] AIMVPPILLG QPSSVTLISG PKTAYESQKE LLSSIGTTRH VSDDIAKASL LDNALLSIMG 180
[0082] GVFEGWVQAL AIVGKAGEDE VDFAALASPF VKSMADWLPR IAGHVREKQY VGGSPLTMQL 240
[0083] EALENISETS RELGVGVLLG SMREVMSEAV KKGKGGESIA GLVPMLTELD KKW 293
[0084] Example 2: Construction of recombinant expression vector
[0085] The nucleotide sequence of the nucleic acid encoding the PociRED is shown in SEQ ID No. 3. Specifically:
[0086] atgagcagca gcaacaaacc gcacgtgagc ctgattggtc tgggcaacat gggcctggca 60
[0087] attgcgaact gtttaattaa gagcggctgt aaactgaccg tgtggaaccg cagcgcggag 120
[0088] aaagcagcca gcctggtccc gcagggagca acggttgctg caacaccggc agaatgtgtt 180
[0089] gcctcaagcc cgaccatcgt gatttgtctg ttaaatcagg atgtggtgca gcagaccctg 240
[0090] gatgaagtta ttgatttaag cggaaaaaca atcatcaacc tgacaaatgg aacgccgcag 300
[0091] caggcagtta aagttgcgac cctggttcag cagcgtggtg cggaaagtta tattcatggc 360
[0092] gcaattatga cgactccgga gtatctgggc cagccatcta gcgttacact gatttcaggt 420
[0093] ccgaaaacag cttatgaatc tcagaaagaa ctgctgagca gcattgggac gacccgtcat 480
[0094] gttagcgatg atattgccaa agcaagctta ttagacaatg cacttctgag cgttatgagt 540
[0095]
[0096] The gene encoding Pocired was inserted into the restriction site Nde I / HindIII on the pET28a plasmid by one-step cloning to obtain the recombinant expression vector pET28a-PocIRED.
[0097] The PCR conditions are: 95℃ 5min; 98℃ 10s, 55℃ 5s, 72℃ 35s (25 cycles); 72℃ 10min, after which the PCR amplification product is verified and recovered by 1% agarose gel electrophoresis. The specific method of one-step cloning is: mix the target fragment (0.03pmol) and the NdeⅠ / HindⅢ enzyme linearized vector (0.01pmol) in the same PCR tube, add 5μL of the enzyme ClonExpress Mix (2×) purchased from Novozymes, add ddH2O to make up to 10μL, and react at 50℃ for 15min. The specific primer sequences are as follows:
[0098] Primer 1 (SEQ ID No.4):
[0099] CCGGAATTCATGA ATCTGC GTGAAAAATAC
[0100] Primer 2 (SEQ ID No.5):
[0101] CCGCTCGAGTTAA TTGTTGC TATAGAAGC
[0102] Example 3: Construction of recombinant expression transformants
[0103] The recombinant expression vector pET28a-PocIRED was transformed into E. coli BL21 (DE3) using the heat shock method familiar to those skilled in the art, thereby obtaining recombinant E. coli BL21 (DE3) / pET28a-PocIRED recombinant expression transformants.
[0104] The basic operation of heat shock method is as follows:
[0105] (1) Take a tube of prepared E. coli BL21 (DE3) competent cells and place it in an ice bath.
[0106] (2) Add 1 / 5 volume of the recombinant expression vector solution to the competent cell suspension, mix gently, and place on ice for 30 min.
[0107] (3) After ice bath, place the mixture in 42°C for pulse heat shock for 90 seconds, quickly transfer to ice bath for 2 minutes, add 800 μL LB culture medium, and transfer to 37°C for 40 minutes.
[0108] (4) Take an appropriate amount of the transformed competent cell suspension and spread it on an LB plate containing 100 μg / mL kanamycin. Incubate the plate upside down at 37°C for 12 to 16 hours to grow recombinant expression transformants.
[0109] (5) Pick a single colony for the next step of the experiment.
[0110] Testing of positive clones:
[0111] (1) Under sterile conditions, 10 single clones were randomly picked from the transformation plate and placed in an Eppendorf tube containing LB liquid medium (containing kanamycin) and cultured at 37°C and 180 rpm until the medium became turbid.
[0112] (2) Under sterile conditions, 2 μL of bacterial solution was taken as template and amplified using the EasyTaqMix system and pET28a universal T7 primer.
[0113] (3) Agarose gel electrophoresis showed that a band appeared at 900 bp, indicating that the clone was a positive clone and the recombinant expression transformant E. coli BL21 (DE3) / pET28a-PocIRED was successfully constructed.
[0114] Blank control: sterile water was used instead of the above 2 μL bacterial solution as a template for amplification, and agarose nucleic acid gel electrophoresis detected that only a band appeared at the position around 250 bp.
[0115] Example 4: Protein expression analysis of recombinant expression transformants
[0116] There is no particular limitation on the culture method and culture conditions of the recombinant expression transformant of the present invention. They can be appropriately selected according to common knowledge in the art based on factors such as the host cell type and culture method, as long as the recombinant expression transformant can grow and produce the imine reductase of the present invention.
[0117] The E. coli culture system familiar to those skilled in the art is used to culture the recombinant expression transformant and express the protein.
[0118] The recombinant expression transformant constructed as described above was inoculated into LB medium containing kanamycin and cultured overnight at 37°C and 180 rpm. A 1% (v / v) inoculum was inoculated into a 500 mL Erlenmeyer flask containing 100 mL LB medium (containing kanamycin) and cultured in a shaker at 37°C and 180 rpm. When the OD of the culture solution reached 600When it reached 0.6, isopropyl-β-D-thiogalactoside (IPTG) was added as an inducer at a final concentration of 0.2 mM. After induction at 16°C for 24 h, the culture solution was centrifuged, the precipitate was collected, and then washed twice with physiological saline to obtain recombinant expression transformant cells.
[0119] Resuspend the above 1g recombinant expression transformant cells with 10mL KPB buffer (100mM, pH 8.0), use an ultrasonic disruptor at 400w power in an ice water bath, work for 4s, rest for 6s, work for 15min, then centrifuge the disrupted liquid at 4℃, 12000rpm and collect the supernatant. Resuspend the precipitate with 10mL KPB buffer (100mM, pH 8.0). Take 80μL of the disrupted supernatant and the precipitate resuspension in a 1.5mL Eppendorf tube, mix with 20μL 5×SDS PAGE Loading Buffer, heat in a boiling water bath or 95℃ metal bath for 5min, and the sample is immediately subjected to SDS-PAGE analysis.
[0120] The results of SDS-PAGE showed that the target protein expressed by the recombinant expression transformant constructed by the present invention could account for more than 50% of the total protein, and 95% of the target protein was expressed in a soluble form.
[0121] Example 5: Reactivity determination of imine reductase
[0122] The enzymatic reaction of analytical scale was carried out to determine the reaction performance of the imine reductase and its mutants. The assay method and conditions are as follows: 400 μL reaction volume contains 200 μL cell-free extract enzyme solution, 15 mM (final concentration, the same below) racemic 1-benzyl-4-methylpiperidin-3-one substrate, 200 mM methylamine, 1 mM NADP + , 1mg / mL BmGDH, 22.5mM glucose, 5% v / v dimethyl sulfoxide, stirred at 800rpm for 24h at 30℃ and KPB buffer (100mM, pH 7.0). Then 40μL of 10M NaOH solution was used to quench the reaction, 500μL of ethyl acetate was added to extract the target reaction, centrifuged to take the supernatant, dehydrated with anhydrous Na2SO4, filtered with a 0.22μm pore size filter membrane, and then chiral GC analysis was performed to determine the conversion rate of the substrate and the ee and dr values of the product (conversion: 98%; ee:>99.9%; dr: 99:1).
[0123] Example 6: Site-directed saturation mutagenesis of the imine reductase Pocired
[0124] The whole plasmid PCR amplification technique was used to perform site-directed saturation mutagenesis on the imine reductase Pocired gene sequence, and the template used was the recombinant plasmid pET28a-PocIRED of the imine reductase Pocired.
[0125] The PCR reaction system was as follows: 1.0 ng template, 0.5 μL (10 μM) of each pair of mutation primers, 12.5 μL PrimeSTARHS (Premix), and sterile distilled water to 25 μL.
[0126] The following are the primers for mutant M1 in the following examples (the primers for other mutants can be introduced by site-directed mutagenesis):
[0127] Mutant M1 Primer 1 (SEQ ID No. 6):
[0128] GTCGCCGTTAACCATGNNKCTGGAAGCTCTGGAAAA
[0129] Mutant M1 Primer 2 (SEQ ID No. 7):
[0130] TTTTCCAGAGCTTCCAGMNNCATGGTTAACGGCGAC
[0131] The PCR amplification procedure was as follows: (1) denaturation at 98°C for 10 s; (2) denaturation at 98°C for 10 s, (3) annealing at 55°C for 10 s, and (4) extension at 72°C for 7 min. Steps (2)–(4) were repeated for 20 cycles, followed by extension at 72°C for 7 min, and the product was stored at 12°C.
[0132] After the PCR amplification product was purified, the PCR amplification product was digested with restriction endonuclease Dpn I at 37°C for 2h, then transformed into E.coli BL21 (DE3) competent cells, and evenly spread on LB agar plates containing 50μg / mL kanamycin, and cultured at 37°C overnight to construct a random mutant library. Single clones were selected to culture in deep-well plates, and each well of the primary plate contained 300μL LB medium (containing 50μg / mL kanamycin) and cultured at 37°C and 800rpm overnight. 50μL of the primary seed solution was transferred to each well of the secondary plate containing 400μL LB medium (containing 50μg / mL kanamycin), cultured at 37°C and 800rpm for 3-4h, and 50μL 2mM IPTG (final concentration 0.2mM) was added to each well for induction, and cultured at 20°C for 16-18h. The deep-well plate was centrifuged at 3500 rpm and 4°C for 10 min, the supernatant was discarded, 200 μL of lysis solution (Tris-Hcl solution (100 mM, pH 9.0) containing 1.5 g / L lysozyme and 0.01 mg / L DNase I enzyme) was added to each well, the cells were fully suspended by shaking, and incubated at 37°C for 1 h. 200 μL of Tris-Hcl solution (100 mM, pH 9.0) was added to each well and centrifuged at 3500 rpm and 4°C for 15 min.
[0133] The mutant screening method is as follows:
[0134] Take 190 μL of the above lysate from each well, centrifuge and transfer the supernatant to a new deep-well plate. Add 1 mM NADP + , 75mM glucose, 20% (v / v) DMSO, 3mg / mL glucose dehydrogenase crude powder, 50mM racemic 1-benzyl-4-methylpiperidin-3-one and 200mM methylamine hydrochloride, each well volume is supplemented to 400μL with Tris-Hcl solution (100mM, pH 9.0), and reacted at 37℃, 800rpm for 24h. 1200μL methanol was added to each well to terminate the reaction, and the reaction was shaken at 800rpm for 5min. Then the deep well plate was placed at 3,500rpm and 4℃ for 15min. 200μL was taken out from each well and transferred to the ELISA plate, and the conversion rate was analyzed by UPLC.
[0135] Example 7: Activity determination of imine reductase Pocired and its mutants
[0136] The activity test system contains 50mM racemic 1-benzyl-4-methylpiperidin-3-one, 1000mM methylamine, 1mM NADP +, 200mM glucose, 15% (v / v) DMSO, the supernatant after centrifugation of imine reductase or mutant lysate and 400μL Tris-Hcl solution (100mM, pH 9.0) of 2mg / mL glucose dehydrogenase crude enzyme powder were reacted at 330℃ and 800rpm to determine the conversion rate in the initial stage of the reaction. 30μL 10M sodium hydroxide solution was added to each well to terminate the reaction and 500μL methyl tert-butyl ether was used for extraction. The organic phase was dried over anhydrous magnesium sulfate and the conversion rate was analyzed by gas phase, and the enzyme specific activity was calculated based on the conversion rate. The results are shown in Table 1.
[0137] Table 1 Enzyme activities of Pocired and its mutants
[0138]
[0139]
[0140] In Table 1, WT refers to Pocired,
[0141] M1 refers to the mutant (11) in the present invention, i.e., the glutamine at position 239 of the amino acid sequence shown in SEQ ID No. 1 is replaced by glycine;
[0142] M2 refers to mutant (12) in the present invention, i.e., the glutamine at position 239 of the amino acid sequence shown in SEQ ID No. 1 is replaced by glycine, and the proline at position 125 is replaced by threonine;
[0143] M3 refers to mutant (13) in the present invention, i.e., in the amino acid sequence as shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, and leucine at position 128 is replaced by tyrosine;
[0144] M4 refers to mutant (14) in the present invention, i.e., in the amino acid sequence as shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, and lysine at position 195 is replaced by alanine;
[0145] M5 refers to mutant (15) in the present invention, i.e., in the amino acid sequence as shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, lysine at position 195 is replaced by alanine, glycine at position 180 is replaced by serine, arginine at position 220 is replaced by valine, alanine at position 47 is replaced by proline, and valine at position 50 is replaced by alanine;
[0146] M6 refers to mutant (16) in the present invention, i.e., in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, lysine at position 195 is replaced by The amino acid sequence of M6 is shown in SEQ ID NO.2, which is as follows:
[0147] MSSSNKPHVS LIGLGNMGLA IANCLIKSGC KLTVWNRSAE KAASLVPQGA TVAATPAECV 60
[0148] ASSPTIVICL LNQDVVQQTL DEVIDLSGKT IINLTNGTPQ QAVKVATLVQ QRGAESYIHG 120
[0149] AIMTTPEYLG QPSSVTLISG PKTAYESQKE LLSSIGTTRH VSDDIAKASL LDNALLSVMS 180
[0150] GVFEGWVQAL AIVGAAGEDE VDFAALASPL VASMADQLPV IAGRVREKQY VGGSPITMGL 240
[0151] EALENISETS RELGVGVLLG SMREVMSEAV KKGKGGESIA GLVPMLTELD KKW 293.
[0152] Negative control refers to a blank reaction without adding any imine reductase or mutant of the present application.
[0153] Example 8: Preparation of crude enzyme solution of imine reductase Pocired and its mutants
[0154] The recombinant E. coli constructed as described above was inoculated into TB medium containing kanamycin and cultured overnight at 37°C and 180 rpm. A 1% (v / v) inoculum was inoculated into a 500 mL Erlenmeyer flask containing 100 mL TB medium (containing kanamycin) and cultured in a shaker at 37°C and 180 rpm. When the OD of the culture solution reached 600 When the pH value reaches 0.6, IPTG with a final concentration of 0.2 mM is added as an inducer. After induction at 16°C for 24 hours, the culture solution is centrifuged, the precipitate is collected, and then washed twice with physiological saline to obtain recombinant expression transformant cells. The harvested recombinant cells are suspended in a 10-fold volume (v / w) buffer, ultrasonically disrupted, and the supernatant is collected by centrifugation to obtain the crude enzyme solution of the recombinant imine reductase Pocired or its mutant.
[0155] Example 9: Preparation of crude enzyme powder of imine reductase Pocired and its mutants
[0156] The crude enzyme solution of imine reductase obtained in Example 8 was collected and frozen at -80°C, and then dried at low temperature using a vacuum freeze dryer to obtain crude enzyme powder of imine reductase or its mutant. The obtained crude enzyme powder was stored in a refrigerator at 4°C for convenient use.
[0157] Example 10: Synthesis of Tofacitinib Chiral Amine Building Block Catalyzed by Pocired Mutant M6
[0158] A 500 mL preparation reaction was carried out in a 1L reactor to test the production performance of the catalytic system. The specific operation is as follows. 200 mL of water and 7.5 g of glycine were added to the reactor, stirred evenly, and the pH was adjusted to 9.5 with 10 M sodium hydroxide solution. Subsequently, 33.5 g of methylamine hydrochloride (1000 mM, 1.8 eq.) and 65 g of glucose (1.3 eq.) were added to the reaction system and stirred evenly. 56 g of 1-benzyl-4-methylpiperidin-3-one substrate (550 mM, 110 g / L) was dissolved in 75 mL of cosolvent dimethyl sulfoxide (DMSO, 15% v / v) and added to the reactor. 0.4 g of cofactor NADP was added + (1mM), 0.4g BmGDH freeze-dried enzyme powder (0.8mg / mL) and 5g PocIRED-M6 mutant freeze-dried enzyme powder (10.0mg / mL). Finally, water was added to fill up the reaction volume to 500mL. The reaction mixture was stirred at 30℃ and 600rpm for 24h. During the reaction, 1.5M methylamine aqueous solution was used to titrate the reaction system to maintain the pH at 9.5. During this period, samples were taken to detect the reaction conversion rate by GC-MS, and the reaction conversion rate reached 93% in 24h. Acetic acid was added to pH 3.0 and stirred for 10min to quench the reaction system. 25g diatomaceous earth was added and stirred for 30min to adsorb the protein precipitated by acid denaturation. The reaction mixture was filtered to remove the diatomaceous earth-protein complex and other insoluble impurities, and the filter cake was washed with 1M hydrochloric acid and combined with the reaction mixture. Impurities in the reaction mixture were removed by extraction with dichloromethane (1L×4). The pH of the reaction mixture was adjusted to 11-12 by 10M sodium hydroxide solution, and then the target product was extracted with ethyl acetate (1L×3). The organic phases were collected and combined, dehydrated with anhydrous Na2SO4, and then evaporated under reduced pressure to obtain 49.5g of brown oily product (74% yield, >99.9% ee, and 98:2dr).
[0159] Example 11: Determination of the reaction performance of the imine reductase Pocired parent (WT) and its mutant (M6) to different substrates
[0160] The imine reductase PocIRED parent (WT) and its mutant (M6) catalyze the racemic 1-benzyl-4-methylpiperidin-3-one substrate and its analogs to obtain a series of structurally similar chiral amine building blocks, and this series of chiral amine building blocks can be used to synthesize the drug tofacitinib. Specific reaction performance characterization is as follows Figure 1 shown.
[0161] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.
Claims
1. A mutant of imine reductase, characterized in that It is a derivative protein with a new amino acid sequence formed by replacing one or more amino acid residues in the amino acid sequence shown in SEQ ID No. 1, namely glycine at position 239, proline at position 125, serine at position 40, valine at position 124, isoleucine at position 127, leucine at position 128, serine at position 72, tyrosine at position 73, threonine at position 76, lysine at position 195, glycine at position 180, arginine at position 220, alanine at position 47, valine at position 50, phenylalanine at position 210, lysine at position 212, tryptophan at position 217, isoleucine at position 178, histidine at position 224 or leucine at position 236 with other amino acid residues.
2. The imine reductase mutant according to claim 1, characterized in that The imine reductase mutant has one of the following sequences: (1) the glutamine at position 239 of the amino acid sequence shown in SEQ ID No. 1 is replaced by glycine, the proline at position 125 is replaced by threonine, and the serine at position 40 is replaced by glutamic acid; (2) the serine at position 72 of the amino acid sequence shown in SEQ ID No. 1 is replaced by asparagine, the tyrosine at position 73 is replaced by glutamine, the threonine at position 76 is replaced by valine, the lysine at position 195 is replaced by alanine, and the glycine at position 180 is replaced by serine; (3) in the amino acid sequence shown in SEQ ID No. 1, the proline at position 125 is replaced by threonine, the serine at position 40 is replaced by glutamic acid, the valine at position 124 is replaced by threonine, the isoleucine at position 127 is replaced by glutamic acid, the leucine at position 128 is replaced by tyrosine, the serine at position 72 is replaced by asparagine, the tyrosine at position 73 is replaced by glutamine, and the threonine at position 76 is replaced by valine; (4) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, lysine at position 195 is replaced by alanine, glycine at position 180 is replaced by serine, and arginine at position 220 is replaced by valine; (5) replacing the proline at position 125 of the amino acid sequence shown in SEQ ID No. 1 with threonine; (6) in the amino acid sequence shown in SEQ ID No. 1, the phenylalanine at position 210 is replaced by leucine, the lysine at position 212 is replaced by alanine, the tryptophan at position 217 is replaced by glutamine, the isoleucine at position 178 is replaced by valine, the histidine at position 224 is replaced by arginine, and the leucine at position 236 is replaced by isoleucine; (7) in the amino acid sequence shown in SEQ ID No. 1, the arginine at position 220 is replaced by valine, the alanine at position 47 is replaced by proline, the valine at position 50 is replaced by alanine, the phenylalanine at position 210 is replaced by leucine, the lysine at position 212 is replaced by alanine, the tryptophan at position 217 is replaced by glutamine, the isoleucine at position 178 is replaced by valine, the histidine at position 224 is replaced by arginine, and the leucine at position 236 is replaced by isoleucine; (8) the glutamine at position 239 of the amino acid sequence shown in SEQ ID No. 1 is replaced by glycine, the proline at position 125 is replaced by threonine, and the serine at position 40 is replaced by glutamic acid; (9) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, lysine at position 195 is replaced by alanine, glycine at position 180 is replaced by serine, arginine at position 220 is replaced by valine, alanine at position 47 is replaced by proline, valine at position 50 is replaced by alanine, phenylalanine at position 210 is replaced by leucine, and lysine at position 212 is replaced by alanine; (10) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, lysine at position 195 is replaced by alanine, glycine at position 180 is replaced by serine, arginine at position 220 is replaced by valine, alanine at position 47 is replaced by proline, valine at position 50 is replaced by alanine, phenylalanine at position 210 is replaced by leucine, lysine at position 212 is replaced by alanine, tryptophan at position 217 is replaced by glutamine, isoleucine at position 178 is replaced by valine, histidine at position 224 is replaced by arginine, and leucine at position 236 is replaced by isoleucine; (11) replacing the glutamine at position 239 of the amino acid sequence shown in SEQ ID No. 1 with glycine; (12) the glutamine at position 239 of the amino acid sequence shown in SEQ ID No. 1 is replaced by glycine, and the proline at position 125 is replaced by threonine; (13) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, and leucine at position 128 is replaced by tyrosine; (14) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, and lysine at position 195 is replaced by alanine; (15) in the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, lysine at position 195 is replaced by alanine, glycine at position 180 is replaced by serine, arginine at position 220 is replaced by valine, alanine at position 47 is replaced by proline, and valine at position 50 is replaced by alanine; (16) In the amino acid sequence shown in SEQ ID No. 1, glutamine at position 239 is replaced by glycine, proline at position 125 is replaced by threonine, serine at position 40 is replaced by glutamic acid, valine at position 124 is replaced by threonine, isoleucine at position 127 is replaced by glutamic acid, leucine at position 128 is replaced by tyrosine, serine at position 72 is replaced by asparagine, tyrosine at position 73 is replaced by glutamine, threonine at position 76 is replaced by valine, and lysine at position 195 is replaced by The amino acid residues at position 170 were replaced by alanine, the glycine at position 180 was replaced by serine, the arginine at position 220 was replaced by valine, the alanine at position 47 was replaced by proline, the valine at position 50 was replaced by alanine, the phenylalanine at position 210 was replaced by leucine, the lysine at position 212 was replaced by alanine, the tryptophan at position 217 was replaced by glutamine, the isoleucine at position 178 was replaced by valine, the histidine at position 224 was replaced by arginine, and the leucine at position 236 was replaced by isoleucine.
3. An isolated nucleic acid, characterized in that The nucleic acid encodes the imine reductase mutant according to claim 1 or 2.
4. A recombinant expression vector, characterized in that: The recombinant expression vector comprises the nucleic acid according to claim 3.
5. A recombinant expression transformant, characterized in that: The recombinant expression transformant comprises the recombinant expression vector according to claim 4.
6. A recombinant imine reductase mutant catalyst, characterized in that: The recombinant imine reductase mutant catalyst is any one of the following forms: (1) culturing the recombinant expression transformant according to claim 5, and isolating transformant cells containing the imine reductase mutant; (2) culturing the recombinant expression transformant according to claim 5, and isolating a crude enzyme solution containing the imine reductase mutant; (3) Drying the crude enzyme liquid containing the imine reductase mutant to obtain crude enzyme powder.
7. A method for preparing tofacitinib chiral amine building blocks by enzymatic conversion, characterized in that: The racemic precursor ketone is used as a substrate and in the presence of the coenzyme NADPH, the racemic precursor ketone is catalyzed by the dynamic kinetic resolution-asymmetric reductive amination using the imine reductase mutant described in claim 1 or 2 or the recombinant imine reductase mutant catalyst described in claim 6 to prepare the tofacitinib chiral amine building block.
8. The method according to claim 7, characterized in that The dehydrogenation reaction catalyzed by dehydrogenase is coupled to NADP + Enzymatic reduction regenerates NADPH; during the reaction, the coenzyme NADPH is oxidized to NADP + , using dehydrogenase to catalyze NADP + Reduction regenerates into NADPH; The dehydrogenase is any one of formate dehydrogenase, glucose dehydrogenase or alcohol dehydrogenase.
9. The method according to claim 8, characterized in that The reaction conditions are: the concentration of the racemic precursor ketone of the substrate is 1-200 g / L, the molar ratio of glucose to substrate is 1.0-2.0, and the NADP + The addition amount is 0.05-2.0mmol / L, pH 4.0-10.0, and temperature is 20-40℃.
10. The method according to claim 7, characterized in that The substrate for synthesizing the tofacitinib chiral amine building block is selected from any of the following compounds represented by the chemical formula:
Citation Information
Cited By
Imine reductase mutant as well as preparation method and application thereof
CN120866254A
An imine reductase mutant, its preparation method and uses
CN120866254B
Method for preparing chiral alpha-trifluoromethyl alcohol by using imine reductase AtRedAm
CN121538277A
Imine reductase mutant and use thereof in preparation of tofacitinib chiral amine building block
WO2026031445A1
